Loxoprofen sodium, a non-selective NSAID, reduces atherosclerosis in mice by reducing inflammation

Journal of Clinical Biochemistry and Nutrition

Volumn 47, Issue 2, 2010, Pages 138-147

  Hamaguchi, Masahide ^a   Seno, Takahiro ^a   Yamamoto, Aihiro ^a   Kohno, Masataka ^a   Kadoya, Masatoshi ^a   Ishino, Hidetaka ^a   Ashihara, Eishi ^b   Kimura, Shinya ^b   Tsubakimoto, Yoshinori ^a   Takata, Hiroki ^a   Yoshikawa, Toshikazu ^a   Maekawa, Taira ^a   Kawahito, Yutaka ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Atherosclerosis; Loxoprofen sodium; Non selective nonsteroidal anti inflammatory drugs

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; LOXOPROFEN; PROSTAGLANDIN SYNTHASE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG INHIBITION; ENZYME IMMUNOASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; TRIACYLGLYCEROL BLOOD LEVEL;

MUS;

EID: 77956608765     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.10-33     Document Type: Article

References (22)

1. del Rincon, I.D., Williams, K., Stern, M.P., Freeman, G.L., and Escalante, A.: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum., 44, 2737-2745, 2001.
2. Van Doornum, S., McColl, G., and Wicks, I.P.: Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum., 46, 862-873, 2002.
3. Gabriel, S.E., Crowson, C.S., Kremers, H.M., Doran, M.F., Turesson, C., O'Fallon, W.M., and Matteson, E.L.: Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum., 48, 54-58, 2003.
4. Stanic, A.K., Stein, C.M., Morgan, A.C., Fazio, S., Linton, M.F., Wakeland, E.K., Olsen, N.J., and Major, A.S.: Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc. Natl. Acad. Sci. U.S.A., 103, 7018-7023, 2006.
5. Westerweel, P.E., Luyten, R.K., Koomans, H.A., Derksen, R.H., and Verhaar, M.C.: Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum., 56, 1384-1396, 2007.
6. Nussmeier, N.A., Whelton, A.A., Brown, M.T., Langford, R.M., Hoeft, A., Parlow, J.L., Boyce, S.W., and Verburg, K.M.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med., 352, 1081-1091, 2005.
7. Mukherjee, D., Nissen, S.E., and Topol, E.J.: Risk of cardiovascular events associated with selective COX-2 inhibitors. J.A.M.A., 286, 954-959, 2001. (Pubitemid 33010342)
8. Hennekens, C.H., Dyken, M.L., and Fuster, V.: Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation, 96, 2751-2753, 1997.
9. Arakawa, T., Fujiwara, Y., Sollano, J.D., Zhu, Q., Kachintorn, U., Rani, A.A., Hahm, K.B., Takahashi, S., Joh, T., Kinoshita, Y., Matsumoto, T., Naito, Y., Takeuchi, K., Yamagami, H., Agustanti, N., Xiong, H., Chen, X., Jang, E.J., Furuta, K., Terano, A., and IGICS study group: A questionnaire-based survey on the prescription of non-steroidal anti-inflammatory drugs by physicians in East Asian countries in 2007. Digestion, 79, 177-185, 2009.
10. Belton, O.A., Duffy, A., Toomey, S., and Fitzgerald, D.J.: Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation, 108, 3017-3023, 2003.
11. Burleigh, M.E., Babaev, V.R., Oates, J.A., Harris, R.C., Gautam, S., Riendeau, D., Marnett, L.J., Morrow, J.D., Fazio, S., and Linton, M.F.: Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation, 105, 1816-1823, 2002.
12. Chenevard, R., Hurlimann, D., Bechir, M., Enseleit, F., Spieker, L., Hermann, M., Riesen, W., Gay, S., Gay, R.E., Neidhart, M., Michel, B., Luscher, T.F., Noll, G., and Ruschitzka, F.: Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation, 107, 405-409, 2003.
13. Tanaka, K., Terada, A., Iizuka, Y., Hayashi, R., Masuda, H., and Mizuno, K.: Loxoprofen Sodium (CS-600), A New Non-steroidal Anti-inflammatory Drug. Sankyo Kenkyusho Nempo, 36, 1-43, 1984.
14. Sudo, T., Ito, H., and Kimura, Y.: Characterization of platelet aggregation in whole blood of laboratory animals by a screen filtration pressure method. Platelets, 14, 239-246, 2003.
15. Okazaki, M., Usui, S., Ishigami, M., Sakai, N., Nakamura, T., Matsuzawa, Y., and Yamashita, S.: Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler. Thromb. Vasc. Biol., 25, 578-584, 2005.
16. Campos, H., Dreon, D.M., and Krauss, R.M.: Associations of hepatic and lipoprotein lipase activities with changes in dietary composition and low density lipoprotein subclasses. J. Lipid. Res., 36, 462-472, 1995.
17. Paigen, B., Morrow, A., Holmes, P.A., Mitchell, D., and Williams, R.A.: Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis, 68, 231-240, 1987.
18. Belton, O., Byrne, D., Kearney, D., Leahy, A., and Fitzgerald, D.J.: Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation, 102, 840-845, 2000.
19. Noguchi, M., Kimoto, A., Gierse, J.K., Walker, M.C., Zweifel, B.S., Nozaki, K., and Sasamata, M.: Enzymologic and pharmacologic profile of loxoprofen sodium and its metabolites. Biol. Pharm. Bull., 28, 2075-2079, 2005.
20. Mason, R.P., Walter, M.F., Day, C.A., and Jacob, R.F.: A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAIDs. Subcell. Biochem., 42, 175-190, 2007.
21. White, W.B., West, C.R., Borer, J.S., Gorelick, P.B., Lavange, L., Pan, S.X., Weiner, E., and Verburg, K.M.: Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am. J. Cardiol., 99, 91-98, 2007.
22. Silverstein, F.E., Faich, G., Goldstein, J.L., Simon, L.S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N.M., Stenson, W.F., Burr, A.M., Zhao, W.W., Kent, J.D., Lefkowith, J.B., Verburg, K.M., and Geis, G.S.: Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J.A.M.A., 284, 1247-1255, 2000.